Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study

Goh, Zhong; Latimer, Maya; Lewis, K.L.; Cheah, Chan Y.; Ciaccio, Pietro R Di; Cushion, Tania; Hawkes, Eliza A; Harrop, Sean; Ku, Matthew; Campbell, Ashlea; Hamad, Nada; Wood, Erica M.; Chung, Eliza; Chen, Pin-Yen; Cochrane, Tara

doi:10.1016/j.clml.2023.01.014

Cited by 8 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, observational studies suggest that anthracycline-free regimens are associated with worse lymphoma outcomes for both lymphoma types. 7 , 23 , 24 , 25 , 26 …”

Section: Discussionmentioning

confidence: 99%

“… 33 Although novel agents may eventually eliminate the need for anthracyclines, at the present time, anthracycline-based regimens are associated with better lymphoma outcomes even in older patients with comorbidities, although further studies are needed to assess optimal regimens for patients with pre-existing HF, multiple comorbidities, or documented geriatric syndrome. 7 , 23 , 24 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma

Upshaw,

Nelson,

Sweigart

et al. 2024

JACC: CardioOncology

View full text Add to dashboard Cite

“…In addition, observational studies suggest that anthracycline-free regimens are associated with worse lymphoma outcomes for both lymphoma types. 7 , 23 , 24 , 25 , 26 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma

Upshaw,

Nelson,

Sweigart

et al. 2024

JACC: CardioOncology

View full text Add to dashboard Cite

“…Comorbidities and performance status may reduce patients' tolerance to standard therapy or preclude a relatively intensive treatment and ultimately compromise survival. When they are eligible for ABVD and treated similarly to younger patients, elderly patients with cHL may enjoy similar or slightly inferior tumor control rates [91,92]. Patients > 60 years old are prone to chemotherapy-related toxicity with ~5% toxic death rate with ABVD [92] and are definitely ineligible for BEACOPP-escalated approaches.…”

Section: Novel Agents In the First-line Treatment Of Classical Hodgki...mentioning

confidence: 99%

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

Vassilakopoulos,

Liaskas,

Pereyra

et al. 2023

IJMS

View full text Add to dashboard Cite

The long-term survival of Hodgkin lymphoma (HL) patients treated according to the current standard of care is excellent. Combined-modality schedules (ABVD plus radiotherapy) in early-stage disease, along with treatment intensity adaptation to early metabolic response assessed by PET/CT in advanced stage HL, have been the cornerstones of risk stratification and treatment decision-making, minimizing treatment-related complications while keeping efficacy. Nevertheless, a non-negligible number of patients are primary refractory or relapse after front-line treatment. Novel immunotherapeutic agents, namely Brentuximab Vedotin (BV) and immune checkpoint inhibitors (CPI), have already shown outstanding efficacy in a relapsed/refractory setting in recent landmark studies. Several phase 2 single-arm studies suggest that the addition of these agents in the frontline setting could further improve long-term disease control permitting one to reduce the exposure to cytotoxic drugs. However, a longer follow-up is needed. At the time of this writing, the only randomized phase 3 trial so far published is the ECHELON-1, which compares 1 to 1 BV-AVD (Bleomycin is replaced by BV) with standard ABVD in untreated advanced-stage III and IV HL. The ECHELON-1 trial has proven that BV-AVD is safe and more effective both in terms of long-term disease control and overall survival. Just recently, the results of the S1826 SWOG trial demonstrated that the combination nivolumab-AVD (N-AVD) is better than BV-AVD, while preliminary results of other randomized ongoing phase 3 trials incorporating anti-PD-1 in this setting will be soon available. The aim of this review is to present the recent data regarding these novel agents in first-line treatment of HL and to highlight current and future trends which will hopefully reshape the overall management of this disease.

show abstract

“…Hodgkin's lymphoma is a type of cancer that lymphocytes grow out of control, causing swollen lymph nodes. Hodgkin's lymphoma can also be seen in bone marrow transplant patients 4,5 …”

Section: Introductionmentioning

confidence: 99%

“…Hodgkin's lymphoma can also be seen in bone marrow transplant patients. 4,5 HL-associated jaundice has been reported to occur in a low percentage of patients (3%-13%), while the involvement of hepatic is uncommon. 6 Various causes, such as hepatic infiltration, biliary obstruction, or viral infections, could lead to jaundice in HL patients.…”

Section: Introductionmentioning

confidence: 99%

Fatal vanishing bile duct syndrome in Iranian patient with Hodgkin's lymphoma

Shokri,

Shariati,

Veisari

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study

Cited by 8 publications

References 27 publications

Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma

Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

Fatal vanishing bile duct syndrome in Iranian patient with Hodgkin's lymphoma

Contact Info

Product

Resources

About